Apixaban superior to warfarin for reducing brain bleed risk

The DOAC apixaban (Eliquis) is superior to warfarin for decreasing the risk of intracranial haemorrhage (ICH) in patients with atrial fibrillation, according to findings from a new study. The new analysis, published in Blood, is the first to compare the DOAC to traditional warfarin in terms of the risk for ICH. It showed that patients taking apixaban had ...

Already a member?

Login to keep reading.

© 2021 the limbic